Commission and EIB provide CureVac with a €75 million financing for vaccine development and expansion of manufacturing

vaccinations CDC

(CDC, Unsplash)

This article is brought to you in association with the European Commission.


  • European Investment Bank and CureVac sign €75 million loan agreement for the development and large-scale production of vaccines, including CureVac’s vaccine candidate against SARS-CoV-2
  • The EIB loan will support CureVac’s activities to complete its new messenger ribonucleic acid (mRNA) production facility in Tübingen, Germany
  • The transaction is financed under the Infectious Diseases Finance Facility of Horizon 2020, the EU research and innovation programme for 2014-2020

The European Investment Bank (EIB) and CureVac, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimised mRNA, entered into a €75 million loan agreement to support the Company’s ongoing development of vaccines against infectious diseases, including its vaccine candidate CVnCoV aimed at preventing SARS-CoV-2 infections. In addition, the loan will support the Company’s efforts to expand its existing Good Manufacturing Practice (GMP) certified production capabilities and accelerate the completion of its fourth production site in Tübingen, Germany. The EIB financing will be provided in three €25 million tranches upon completion of pre-defined milestones.

Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, said: “The coronavirus will be with us, as long as we do not have a vaccine against it. This is why our work on this front, together with international actors, is so crucial. Recently we have presented our vaccines strategy to accelerate the development, manufacturing and deployment of vaccines against the novel coronavirus. And since the beginning of the pandemic, we increased the funding for the Infectious Diseases Finance Facility by €400 million to allow the EIB to process a higher volume of projects addressing this disease. With our support to CureVac we accelerate our efforts to find safe and effective solutions for everyone in Europe and globally.”

It does not need a pandemic to prove that new vaccines can be breakthroughs for public health,” said Ambroise Fayolle, EIB Vice-President in charge of innovation and health. “But in times like ours it becomes clear just how important they are to keep societies running globally. In fact, the only way to end the dramatic situation the world is facing since the outbreak of the COVID-19 pandemic would be a safe and effective vaccine. Thanks to our cooperation with the European Commission, we can finance more and more innovative biotech and medtech companies, such as CureVac, in their research and development of vaccines, therapeutics and diagnostics solutions. This is an added value of Europe, and the EIB does everything it can to maximise this value for the sake of people.”

Pierre Kemula, Chief Financial Officer of CureVac, added: “We are very pleased with the EIB financing. It allows us to further invest in our mRNA technology platform to fight life-threatening diseases. We are working intensively to develop a safe and effective low dose mRNA vaccine against SARS-CoV-2 and started a Phase 1 clinical trial of CVnCoV in June. We are looking forward to expediting the completion of our industrial-scale production site to provide critically needed supply of innovative mRNA-based vaccines.”

About CureVac’s mRNA technology platform

CureVac’s mRNA technology platform has shown potential in the clinical development and production of mRNA based vaccines and therapeutics. The Company’s proprietary RNAoptimizer® platform aims to optimize the properties of mRNA medicines based on its three core pillars: protein design, mRNA optimization and mRNA delivery. The technology can be tailored to induce varying degrees of immune responses against specific protein antigens of choice, potentially providing potent prophylactic vaccines for the prevention of infectious diseases at a low dose, such as Rabies, as well as immunotherapies for the treatment of cancer. The technology can also be adapted to avoid immune activation for purposes of protein therapy and antibodies, thereby providing potential new therapeutic modalities for patients suffering from a vast range of diseases.

The Infectious Diseases Finance Facility (IDFF) of the EU’s Horizon 2020 programme backs the loan to CureVac. The IDFF is an example of successful collaboration between the European Commission and the EIB in the face of a health crisis. Through the IDFF, the EIB has supported 13 companies with total lending of €316 million for developing cures, vaccines and diagnostics against various infectious diseases, most prominently the coronavirus.

 

Background

The European Investment Bank is the long-term lending institution of the European Union owned by its Member States. It makes long-term finance available for sound investments in order to contribute towards EU policy goals. The EIB also supports investments outside the EU.

The InnovFin Infectious Diseases Finance Facility (IDFF) is a financial product dedicated to support the fight against infectious diseases. The joint European Commission and EIB Group initiative falls under Horizon2020, the 2014-2020 EU research and innovation programme. IDFF enables the EIB to provide between €7.5 million and €75 million of funding to innovative players active in developing vaccines, drugs, medical and diagnostic devices and research infrastructure for combatting infectious diseases. The loans finance clinical trials, market access, and the development of prototypes or industrial roll out of novel equipment, pre-clinical R&D and working capital needs. The IDFF has been reinforced by €400 million to better tackle the outbreak of COVID-19.

CureVac is a leading clinical stage biotechnology company in the field of messenger RNA (mRNA) technology with 20 years of expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.

the sting Milestone

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

I accidentally went viral on TikTok. I learned we failed our youngest generation.

“The Belt and Road Initiative aims to promote peace, development and stability”, Ambassador Zhang of the Chinese Mission to EU highlights from European Business Summit 2018

Our tourism system is broken – time to customize

Dozens of children at risk as clashes in Hudaydah near hospital – UNICEF

Can autonomous cars make traffic jams a thing of the past?

UN chief sends condolences to families of Malawi flood victims

Trade in fake Italian goods costs economy billions of euros

UN envoy ‘encouraged’ by latest talks on avoiding ‘worst-case scenario’ in Syria’s Idlib

5 things to know about the Western Balkans

Countries must make teaching profession more financially and intellectually attractive

Will Brexit shatter the EU or is it still too early to predict?

MEPs commend Ukraine‘s reform efforts and denounce Russian aggression

Budget MEPs approve €104.2 m in EU aid to Greece, Spain, France and Portugal

Containers at the port of Tokyo. (Copyright: European Union, 2016. Source: EC - Audiovisual Service. Photo: Haruyoshi Yamaguchi)

EU cuts fast-track free trade deals with Japan and Singapore and leads the trade scene

Telemedicine and the Brazilian reality

Don’t take African generosity towards refugees for granted, says UN refugee chief

Brexiteer May gets lip-service from Trump and Turkish promises from Erdogan

UNICEF delivers medical supplies to Gaza in wake of deadly protests

New York high school students are getting free water bottles to cut plastic waste

EU: All economic indicators in free fall

8 amazing facts to help you understand China today

Denmark plans ‘Silicon Valley’ on 9 artificial islands off Copenhagen

Deal on digitalisation of access to justice will benefit citizens

The 28 EU leaders show contempt for the European Elections results

First-ever EU defence industry fund to finance joint development of capabilities

Brexit negotiations: back to square one, tougher words, no good faith

Mario Draghi quizzed for last time by Economic and Monetary Affairs Committee

Antimicrobial resistance: how can an intersectoral approach between society and healthcare professionals be developed and applied?

EU Leaders’ meeting in Sofia: Completing a trusted Digital Single Market for the benefit of all

Who will secure Lithuania?

UN condemns Syrian ‘war on children’ as up to 30 reportedly killed in clashes

Number of MEPs to be reduced after EU elections in 2019

How cities are failing to be inclusive – and what they can do about it

Coronavirus: Commission welcomes Parliament’s quick green light for proposed new resources to protect lives and livelihoods

Thursday’s Daily Brief: Poverty report reveals ‘vast inequalities’, measles compounds DRC Ebola woes, Guterres visits Mozambique, Bangladesh update, freedom of expression online

Japan’s holiest shrine is pulled down and rebuilt every 20 years – on purpose

MasterCard at European Business Summit 2015: A focus on innovation will drive inclusive economic growth for Europe

Parliament toughens its position on banking union

Education critical to ensure future of forests, and reverse their destruction

Sustainable Development Goals: making the world a better place

“China is the only BRICS country to have either met or possibly slightly surpassed my expectations”, BRICS inventor Jim O’ Neil from Switzerland; the Sting reports live from World Economic Forum 2015 in Davos

The future of international election observation missions

EU-US resume trade negotiations under the spell of NSA surveillance

Ukraine: Temperatures plunge amid rising humanitarian needs

Russia must urgently step up fight against foreign bribery

Bayer’s cross at night (Copyright: Bayer AG)

The EU clears Bayer-Monsanto merger amid wide competition and environmental concerns

Bank resolutions to remain a politically influenced affair

Asymptomatic, pre-symptomatic, symptomatic: what is the difference?

This AI trash can is designed to stop you wasting food

To hope or doubt? The state of women’s progress in the world

EU, Canada and China co-host international meeting on climate cooperation and a sustainable economic recovery

‘Stand united against anti-Muslim hatred’ urges Guterres, after mosque shootings in New Zealand leave 49 dead

The ocean is teeming with microplastic – a million times more than we thought, suggests new research

UN commission agrees roadmap on ensuring women’s social protection, mobility, safety, and access to economic opportunities

South Africa’s economy in 5 charts

Four things the UN chief wants world leaders to know, at key COP24 climate conference opening

Betazone: The Beauty of Inclusion

5 ways to make your organization a great sustainability partner

“Move fast, build to last: Europe’s new generation” – op-ed by Ursula von der Leyen, President of the European Commission

Why we need a Paris Agreement for nature

More Stings?

Advertising

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s